Preventing patients with multiple sclerosis from developing side effec
Keratinocyte Growth Factor - promoting thymic reconstitution and preventing autoimmunity after alemtuzumab (Campath-1H) treatment of multiple sclerosis. CAM-THY
What was tested
Treatment tested
- Palifermin
Fibroblast growth factor receptor 2 agonist
- Alemtuzumab
CAMPATH-1 antigen inhibitor
What it measured
Main measures
The primary endpoint is incidence of clinical autoimmunity within 30 months of starting treatment with alemtuzumab.
Other measures (1)
• Percentage of naive T cells • Safety outcomes - incidence and nature of adverse events • Percentage of central memory T cells, effector memory T cells and T effector memory RA cells - as determined by flow cytometry • Frequency of recent thymic emigrants (defined by co-expression of CD45RA and CD31 in CD4+ T cells, and by CD45RA and CD103 in CD8+ T cells) - as determined by flow cytometry •
Thinking and memoryImmune responseSafety
Papers
Loading reviews and guidelines…
Related trials
- Therapeutic Monitoring of Drugs Used in the Treatment of Multiple Scle
Phase 4 · Status unknown
No results found
- A phase IV, unicentric, open label clinical trial to evaluate the defa
Phase 4 · Withdrawn
Stopped
- AHSCT With Fludarabine and Cyclophosphamide Based Conditioning Regimes
Phase 1 · Recruiting
Still running
- Relationship Between Oral DMT Burden and Adherence in MS
Status unknown
No results found
- Physical and Cognitive Performance During the Two First Years of Lemtr
Completed
Paper found, not read
- Signatures of Immune Reprogramming in Anti-CD52 Therapy of MS: Markers
Status unknown
Paper found, not read
History
- In scope changed from true to false
Started
Apr 2012